53 related articles for article (PubMed ID: 22569947)
1. The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients.
Feuer EJ; Lee M; Mariotto AB; Cronin KA; Scoppa S; Penson DF; Hachey M; Cynkin L; Carter GA; Campbell D; Percy-Laurry A; Zou Z; Schrag D; Hankey BF
Cancer; 2012 Nov; 118(22):5652-62. PubMed ID: 22569947
[TBL] [Abstract][Full Text] [Related]
2. Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.
Howlader N; Mariotto AB; Woloshin S; Schwartz LM
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):255-64. PubMed ID: 25417239
[TBL] [Abstract][Full Text] [Related]
3. A New Personalized Oral Cancer Survival Calculator to Estimate Risk of Death From Both Oral Cancer and Other Causes.
Davies L; Hankey BF; Wang Z; Zou Z; Scott S; Lee M; Cho H; Feuer EJ
JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):993-1000. PubMed ID: 37429022
[TBL] [Abstract][Full Text] [Related]
4. The impact of state-specific life tables on relative survival.
Stroup AM; Cho H; Scoppa SM; Weir HK; Mariotto AB
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):218-27. PubMed ID: 25417235
[TBL] [Abstract][Full Text] [Related]
5. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
Frendl DM; FitzGerald G; Epstein MM; Allison JJ; Sokoloff MH; Ware JE
PLoS One; 2020; 15(12):e0240039. PubMed ID: 33284845
[TBL] [Abstract][Full Text] [Related]
6. Key Points for Clinicians About the SEER Oral Cancer Survival Calculator.
Davies L; Hankey BF; Wang Z; Zou Z; Scott S; Lee M; Cho H; Feuer EJ
JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):1042-1046. PubMed ID: 37429019
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies.
Weir HK; Johnson CJ; Mariotto AB; Turner D; Wilson RJ; Nishri D; Ward KC
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):198-209. PubMed ID: 25417233
[TBL] [Abstract][Full Text] [Related]
8. Scalable proximal methods for cause-specific hazard modeling with time-varying coefficients.
Wu W; Taylor JMG; Brouwer AF; Luo L; Kang J; Jiang H; He K
Lifetime Data Anal; 2022 Apr; 28(2):194-218. PubMed ID: 35092553
[TBL] [Abstract][Full Text] [Related]
9. The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.
Feuer EJ; Rabin BA; Zou Z; Wang Z; Xiong X; Ellis JL; Steiner JF; Cynkin L; Nekhlyudov L; Bayliss E; Hankey BF
J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):265-74. PubMed ID: 25417240
[TBL] [Abstract][Full Text] [Related]
10. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.
Cho H; Mariotto AB; Mann BS; Klabunde CN; Feuer EJ
Am J Epidemiol; 2013 Aug; 178(3):339-49. PubMed ID: 23825168
[TBL] [Abstract][Full Text] [Related]
11. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.
Edwards BK; Noone AM; Mariotto AB; Simard EP; Boscoe FP; Henley SJ; Jemal A; Cho H; Anderson RN; Kohler BA; Eheman CR; Ward EM
Cancer; 2014 May; 120(9):1290-314. PubMed ID: 24343171
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Risk of Metastatic Recurrence for Female Breast Cancer Patients in the Presence of Competing Causes of Death.
Mariotto AB; Botta L; Bernasconi A; Zou Z; Gatta G; Capocaccia R
Cancer Epidemiol Biomarkers Prev; 2023 Dec; 32(12):1683-1689. PubMed ID: 37707367
[TBL] [Abstract][Full Text] [Related]
13. A population-based model identifying optimal candidate for primary tumor resection in distant metastatic laryngeal carcinoma.
Liu X; Lin P; Shen W; Yang Y
Eur Arch Otorhinolaryngol; 2023 Jun; 280(6):2885-2896. PubMed ID: 36695908
[TBL] [Abstract][Full Text] [Related]
14. Estimating life expectancy adjusted by self-rated health status in the United States: national health interview survey linked to the mortality.
Cho H; Wang Z; Yabroff KR; Liu B; McNeel T; Feuer EJ; Mariotto AB
BMC Public Health; 2022 Jan; 22(1):141. PubMed ID: 35057780
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
16. The influence of multi-morbidities on colorectal cancer screening recommendations and completion.
Coronado GD; Nielson CM; Keast EM; Petrik AF; Suls JM
Cancer Causes Control; 2021 May; 32(5):555-565. PubMed ID: 33687606
[TBL] [Abstract][Full Text] [Related]
17. Multimorbidity: Implications and directions for health psychology and behavioral medicine.
Suls J; Green PA; Boyd CM
Health Psychol; 2019 Sep; 38(9):772-782. PubMed ID: 31436463
[TBL] [Abstract][Full Text] [Related]
18. Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review.
Thurtle D; Rossi SH; Berry B; Pharoah P; Gnanapragasam VJ
BMJ Open; 2019 Jun; 9(6):e029149. PubMed ID: 31230029
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
